Organisation paid for research Program year 2025 Source: CMS Open Payments

Eye Research Foundation

Neither a doctor nor a teaching hospital

Research payments

$3,378,972

154 payments

Through program year 2025, Eye Research Foundation is reported as receiving $3,378,972 in research payments, across 154 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$883,738	36
2024	Research	$327,674	6
2023	Research	$55,771	19
2022	Research	$447,895	22
2021	Research	$860,464	17
2020	Research	$553,626	29
2019	Research	$249,805	25

Breakdown

Who paid Research payments · program years 2019–2025

Oyster Point Pharma, Inc. $1,027,522 32 payments
Aerie Pharmaceuticals, Inc. $836,405 10 payments
Kowa Research Institute, Inc. $496,935 5 payments
Alcon Research LLC $275,036 15 payments
AbbVie, Inc. $222,279 27 payments
Shire North American Group Inc $179,394 2 payments
Vanda Pharmaceuticals Inc. $171,376 3 payments
Mallinckrodt Hospital Products Inc. $52,550 3 payments
Allergan Inc. $45,262 44 payments
Ocular Therapeutix, Inc. $42,475 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease $834,305 9 payments
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis $742,377 17 payments
K-161-201 $496,935 5 payments
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) $277,862 12 payments
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-3) $226,638 5 payments
Study of Shp639 Eye Drops in Adults With High Eye Pressure Or Primary Open-Angle Glaucoma $179,394 2 payments
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye $171,376 3 payments
Phase 1x2F2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia $154,160 3 payments
A Multicenter, Open-Label Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Severe Keratitis $56,050 4 payments
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $44,268 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.